Blueprint Medicines Corp (BPMC): Christoph Lengauer , Chief Scientific Officer of Blueprint Medicines Corp sold 15,872 shares on Apr 13, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $20.01 per share for a total value of $317,598.72 according the SEC Form 4 Filing.
Institutional Investors own 93.68% of Blueprint Medicines Corp shares.During last six month period, the net percent change held by insiders has seen a change of -40.12%.
Shares of Blueprint Medicines Corp (BPMC) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.74 points or -3.54% at $20.16 with 59,884 shares getting traded. Post opening the session at $20.9, the shares hit an intraday low of $20.04 and an intraday high of $20.9 and the price vacillated in this range throughout the day. The company has a market cap of $548 M and the number of outstanding shares has been calculated to be 2,72,01,271 shares. The 52-week high of Blueprint Medicines Corp is $37.17 and the 52-week low is $13.04.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib which is an inhibitor of KIT and PDGFRa is approved in SM and GIST. The Company’s other drug candidate is BLU-554 which targets FGFR4 a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.